Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

The University of British Columbia

$52,000.00

Development of high-throughput techniques and tools enabling glycomic analysis of gastrointestinal mucus

FY 2023-24

Summary
Little attention is paid to mucus unless someone has a runny nose or cough, but it is a substance that plays key roles in the normal functioning of the body. For example, gastrointestinal (GI) mucus (the focus of this DG) prevents the stomach from digesting itself while maintaining, in the large intestine/colon, a delicate balance between the largest collections of microbes and immune cells in the body. A molecular-level understanding how mucus mediates its plethora of functions requires a clear chemical picture of what mucus actually is: a collection (~20) of proteins (dubbed mucins) that are among the largest and most complex found in Nature. All mucins contain protein cores, the biosynthesis of which is strictly dictated by the genetic code. Projecting from these invariant cores-like bristles on a bottle brush-are thousands of chemically-complex polymers (called glycans), each composed of simpler monosaccharides (sugars); just like a few Lego blocks can be put together in a myriad of different ways, so are monosaccharides coupled together by a host of competitive enzymes to yield, in human GI mucins, hundreds of distinct glycans. These glycans collectively account for up to 80% of the total mucin mass, and reflect a person's genetic background, diet, GI microbes, inflammation, stress, sex, or age. Thus, we hypothesize that whole populations of mucus-borne glycans (which can be obtained non-invasively) may reproducibly and selectively reflect both healthy GI function and diseased states. Our longer-term research program is to use mucus glycomics to understand the etiology of GI conditions like irritable bowel disease or colon cancer, while the shorter-term objectives of this specific DG are to systematically meet the chemical challenges (revealed by previously-funded DG research) hindering the accurate and fast glycome analyses need for both hypothesis-generating and clinical studies. We suggest that the single largest impediment to the application of glycomics both clinically and for functional studies, is the fact that current protocols are unable to handle the thousands of samples required to make such research statistically valid. True, there have been some recent tour de force high-throughput (HTP) glycomics projects, almost all of which employed mass spectrometry (MS)-based analyses performed by elite academic labs/institutions. But the lengthy MS turn-around-times are unsuitable for diagnostic applications while entailing low sample replicates in many glycomic studies. The objective of this DG is to change this status quo by adapting widespread DNA sequencers to perform rapid, HTP mucus glycomics analyses. The requested funds will support 15 - 21 students who will gain skills on a wide variety of analytical procedures as they address persistent problems with MS-based glycomic procedures with the goal of enabling GI glycomic analyses to be accomplished in a HTP-format imperative to linking GI mucus glycans to its many functions.
Program
Discovery Grants Program - Individual
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
RGPIN-2023-03615
Name nom
Zandberg, Wesley
Department département
Chemistry
Organization id
2
Institution établissement
The University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2023
Award amount
52000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1504
Committee name en
Chemistry
Committee name fr
Chimie
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
3504
Research subject group en
Analytical chemistry
Research subject group fr
Bioanalytical chemistry
Research subject en
Chimie analytique
Research subject fr
Chimie bioanalytique
Application title
Development of high-throughput techniques and tools enabling glycomic analysis of gastrointestinal mucus
Keyword
biomarkers; capillary electrophoresis; chromatography; Glycomics; high-throughput techniques; mass spectrometry; method development; microbiome; mucus; standard reference materials
Application summary
Little attention is paid to mucus unless someone has a runny nose or cough, but it is a substance that plays key roles in the normal functioning of the body. For example, gastrointestinal (GI) mucus (the focus of this DG) prevents the stomach from digesting itself while maintaining, in the large intestine/colon, a delicate balance between the largest collections of microbes and immune cells in the body. A molecular-level understanding how mucus mediates its plethora of functions requires a clear chemical picture of what mucus actually is: a collection (~20) of proteins (dubbed mucins) that are among the largest and most complex found in Nature. All mucins contain protein cores, the biosynthesis of which is strictly dictated by the genetic code. Projecting from these invariant cores-like bristles on a bottle brush-are thousands of chemically-complex polymers (called glycans), each composed of simpler monosaccharides (sugars); just like a few Lego blocks can be put together in a myriad of different ways, so are monosaccharides coupled together by a host of competitive enzymes to yield, in human GI mucins, hundreds of distinct glycans. These glycans collectively account for up to 80% of the total mucin mass, and reflect a person's genetic background, diet, GI microbes, inflammation, stress, sex, or age. Thus, we hypothesize that whole populations of mucus-borne glycans (which can be obtained non-invasively) may reproducibly and selectively reflect both healthy GI function and diseased states. Our longer-term research program is to use mucus glycomics to understand the etiology of GI conditions like irritable bowel disease or colon cancer, while the shorter-term objectives of this specific DG are to systematically meet the chemical challenges (revealed by previously-funded DG research) hindering the accurate and fast glycome analyses need for both hypothesis-generating and clinical studies. We suggest that the single largest impediment to the application of glycomics both clinically and for functional studies, is the fact that current protocols are unable to handle the thousands of samples required to make such research statistically valid. True, there have been some recent tour de force high-throughput (HTP) glycomics projects, almost all of which employed mass spectrometry (MS)-based analyses performed by elite academic labs/institutions. But the lengthy MS turn-around-times are unsuitable for diagnostic applications while entailing low sample replicates in many glycomic studies. The objective of this DG is to change this status quo by adapting widespread DNA sequencers to perform rapid, HTP mucus glycomics analyses. The requested funds will support 15 - 21 students who will gain skills on a wide variety of analytical procedures as they address persistent problems with MS-based glycomic procedures with the goal of enabling GI glycomic analyses to be accomplished in a HTP-format imperative to linking GI mucus glycans to its many functions.
The University of British Columbia - $52,000 Grant (2… | Canada Spends